Kenneth Lim

Lim Lab: Kenneth Lim, MD, PhD

Developing therapeutic strategies for accelerated cardiovascular disease and premature aging in chronic kidney disease (CKD). Integrating multidisciplinary strategies at the interface of translational and clinical research for improved patient care.


Dr. Kenneth Lim is a Physician-Scientist at the Division of Nephrology, Massachusetts General Hospital and Harvard Medical School. He is a graduate of the University of Cambridge (Christ’s College) and University of Warwick in England. He is an Internist and Nephrologist who has deployed to regions around the world to provide leading medical care and strategic principles to help meet critical needs of victims of humanitarian crises, such as war, poverty and natural disasters. He leads several Clinical and Translational research studies that focuses on accelerated age-related cardiovascular disease, a condition that has earned its place as a leading non-communicable health crisis in both developed and developing nations.

 The major theme of his research is to study mechanisms underlying age-associated cardiac and vascular remodeling in uremic conditions and to identify potential therapeutic targets. His group has an emphasis in multidisciplinary collaboration with projects that draw from an international talent pool. In collaboration with Dr. Tzong-shi Lu at the Renal Division, Brigham and Women’s Hospital and Dr. Thomas Hiemstra at the Clinical Trials Unit, University of Cambridge – his group spearheads several human tissue translational research studies:

The CAIN (Cardiac Aging in CKD) study: The study investigates the development of uremic cardiomyopathy and cardiac fibrosis in CKD utilizing a unique and rare collection of explanted human heart tissues collected for research purposes.

The VAGE (Vascular Anti-aGing stratEgies) study: The study investigates age-associated arterial changes in CKD. Parallel applanation tonometry and echocardiographic measures allow the linking of clinical outcomes with molecular changes using arterial explants.

Multidisciplinary approaches applies next-generation RNA sequencing technology, targeted proteomics and ex vivo organ culture models to study myocardial and arterial changes.

In collaboration with Dr. Thomas Hiemstra (Cambridge University) and Dr. Daniel Zehnder (North Cumbria University Hospitals NHS Trust, UK), the BHF-CPET study utilizes state-of-the-art cardiopulmonary exercise testing (CPET) technology to accurately assess cardiovascular functional reserve before and after kidney transplantation. 


In 2018, Dr. Lim became one of the first US doctors to respond to the Volcano Fuego eruption in Guatemala. He was featured on MGH news for his international medical work:

Back to Top